Search from website
Search from website
Figure 1. Coomassie-stained SDS-PAGE analysis of monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 22F9. 4-12% gradient gel is used for analysis. Lane 1. Monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 22F9 (-DTT). Lane 2. Size marker. Lane 3. Monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 22F9 (+DTT).
Figure 2. HPLC analytical SEC for final product.
Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.
Figure 4. Octet RED96e analysis, antibody was loaded on sensor for capture of Nucleocapsid protein.
Catalogue #
R1-149-100
Name
Human IgG1-lambda antibody to SARS CoV-2 NP (clone 22F9)
Target
Nucleocapsid protein SARS-CoV-2
Target Description
Recombinant SARS-CoV-2 Nucleocapsid protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line
Clonality
Human monoclonal
Clone
22F9
Class
hIgG1
Reactivity
SARS-CoV-2 Nucleocapsid protein
Dissociation constant (KD)
< 1.0 x 10-12 M
Application
ELISA, WB
Kd:
< 1.0 x 10-12 M
ELISA:
0,08-0,16 µg/ml
WB:
0,5-1 µg/ml
Purification
Protein A affinity chromatography
Buffer
PBS pH 7.4
Shipping
Shipped at ambient temperature.
Storage
Store at +4 °C. Avoid multiple freeze-thaw cycles.
This product is for research use only
TECHNICAL ASSISTANCE
Please refer any technical questions to
technical.support@icosagen.com
© 2024 Icosagen
